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Anti-in￿ ammatory actions of two anti-allergic
drugs, alone or with dexamethasone (Dex) were
examined in two models, because in￿ ammation
is claimed to be important for allergic events,
especially for asthma. Cromoglycate and nedocro-
mil were tested in ischaemic- and histamine-
induced paw oedema models of mice. These anti-
allergic drugs (1±100 mg/kg, i.p.) failed to sup-
press these oedemata, but enhanced the sup-
pressions by a low dose of dexamethasone
(0.1 mg/kg, s.c.) at 3±8 h after Dex injection. The
mode of effects by anti-allergic drugs resembled
that of a natural antioxidant (a-tocopherol, b-
carotene etc.), and was different from that of an
immunosuppressant like FK506. The enhancing
potencies of the two anti-allergic drugs were
similar at 6 h after Dex in both oedemata, and
were diminished by superoxide dismutase (SOD)
or catalase (i.p.). Cycloheximide completely abol-
ished suppressions. Nedocromil, but not cromo-
glycate, inhibits in￿ ammatory events. Therefore,
there are common unknown actions by which
the two anti-allergics enhance suppression by
Dex. A possible mechanism of this action was
supposed to enhance the superoxide and/or
hydrogen peroxide-dependent glucocorticoid re-
ceptor (GR) signalling in the target cells.
Key words: Cromoglycate, Nedocromil, Dexa-
methasone, Ischaemic paw oedema, Histamine paw
oedema, Asthma, Superoxide dismutase, Catalase,
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Introduction
The effect of glucocorticoid (GC) appears in
most models several hours after its dosing,
because GC needs a lag time to induce the
directly acting anti-in￿ammatory or anti-ischae-
mic proteins such as macrocortin (recently
referred to as lipocortin)1 and vasoregulin.2
Typical GC, dexamethasone (Dex) or cortisol did
not suppress ischaemic and histamine paw
oedema of mice at 1 h after injection and
showed a suppression peak at 3 h. However,
when mice were pretreated by an immunosup-
pressant like FK506 (0.01±1 mg/kg, oral), sup-
pression appeared earlier, at 30 min and 1 h after
Dex. FK506 increased the suppression at 3 h,
but not at 6 h after Dex injection.3 Pretreatment
by a natural antioxidant (a-tocopherol, b-caro-
tene etc.) did not suppress the paw oedemata at
1 h after Dex, and enhanced the suppression at
3±18 h after Dex. ED30 of them (i.p.) at 6 h after
Dex was from 0.02 (morin) to 12 mg/kg (ascor-
bate) when 0.1mg/kg Dex alone suppressed
12%of ischaemic oedema (submitted).
The main aim of this work was whether anti-
allergic drugs, cromolycate and nedocromil,
increase the oedema suppression by Dex, be-
cause nedocromil is reported to possess more
anti-in￿ammatory effects than other anti-allergic
drugs.4 Nedocromil signi￿cantly inhibited the
release of histamine, leukotriene C4 (LTC4) and
prostaglandin D2 (PGD 2) from bronchoalveolar
cells in response to stimulation with antigen or
antibody to human IgE. Cromoglycate had less
than 1/200 the potency of nedocromil in these
cells and failed to inhibit the antigen-induced
bronchoconstriction in the Ascaris-sensitized
primate Macaca arctoides. Nedocromil, but not
cromoglycate, inhibited IgE-induced beta-hexo-
saminidase release from rat bone marrow-
derived mast cells in spite of the fact that both
drugs inhibited the release from peritoneal mast
cells.5 Although cromoglycate is used success-
fully in the treatment of asthma, it was recog-
nized that the compound has limitations in the
treatment of certain patients with intrinsic
asthmatic and those in the older age group.
Lately developed nedocromil was expected to
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an anti-in￿ammatory character.4 Nedocromil
(1±10 mM) was also stronger as an anti-allergic
drug than cromoglycate (10±100 mM) in in
vitro tests. These drugs inhibited the anti-IgE-
induced histamine release from bronchoalveolar
lavage (BAL) cells of normal subject (12 males,
age 22±74 years).6 The anti-asthmatic action of
cromoglycate has been supposed to affect
sensory nerves which can in￿uence the airway
calibre, because this drug is neither atropine-
like, nor anti-histamine and it does not relax the
bronchial smooth muscle.7 More potent sup-
pression by nedocromil than cromoglycate was
expected with Dex in our ischaemic and
histamine paw oedema after these reports.
Nevertheless, these drugs were equipotent to
suppress our models, suggesting that they have
still another common unknown capacity to
enhance the oedema suppression which resem-
bles that of a certain natural antioxidant. In this
experiment, the enhancement of Dex action by
cromoglycate or nedocromil was impaired by
superoxide dismutase (SOD) and catalase, but
not by a nitric oxide synthase (NOS) inhibitor.
This suggests that the endogenous amount of
superoxide radical (O2- ) and/or hydrogen per-
oxide (H 2O2) were required for Dex action
which was enhanced by cromoglycate or nedo-
cromil.
Materials and Methods
Animals and assay
Male ddY mice were obtained from SLC Co.
(Shizuoka) and weighed 1±2 h before the ex-
periment to select 30±36 g mice after keeping
in room temperature for at least 1 day. The
binding of the right hind paw with a commer-
cial rubber ring (1 3 1 mm, d= 42 mm) was
served to induce ischaemia. Mice with various
amounts of rubber binding (8±14 times) just
above the articulation were examined with
different duration of ischaemia (5±120 min) and
duration of natural blood recirculation (5±
180 min) after scissoring off the rubber. Ischae-
mic paw oedema provoked by 20 min ischaemia
with 10 times of rubber binding followed by
20 min recirculation, was found to be the best
for evaluating the suppression or enhancement
by the drug. The rubber binding was performed
under light ether anaesthesia which was per-
mitted by the ethical guide line of the Japan
Experimental Animal Association. Details of the
manipulation using a plastic cylinder device
was in our previous report.8 The increase of
paw thickness (not circumference) was ob-
tained as a difference of thickness measured
with Citizen Thickness gauge (Citizen Watch
Co., Tokyo) before and after the ischaemic
insult. The average increase of paw thickness in
control animals was 0.77±0.83 mm (n = 5, 18
experiments). Assays were performed at 1, 3, 6
and 18 h after Dex. Histamine paw oedema was
induced by 10 ml of saline solution containing
net 3 mg histamine.3 Paw swellings of control
mice was 0.79±0.88mm after 13 min when the
paw swelled to maximum (n = 5, 15 experi-
ments). Drug solution was prepared 1 to 3 h
before injection (0.2ml/10 g body weight, i.p.).
Dex (0.2ml/10 g body weight, s.c.) was in-
jected 30 min after anti-allergic drug. Inhibitor
(SOD etc., saline solution) was injected
(0.2 ml/10 g body weight) just before anti-
allergic drug. The increased paw thickness of
drug- and/or inhibitor-treated mouse (n = 3)
were compared with the average value of
control (n = 5) in each experimental day for
calculation of suppression. Tests for one dose
were repeated four times on different days
(n = 12 in total). Suppression was expressed as
the mean standard error (SE) of the mean.
Statistical signi￿cance was determined using
Student’s paired t-test.
Drugs
Dexamethasone (Dex, Decadoron®, 4 mg/ml as
phosphate ester) was purchased from Banyu
Pharmaceutical Co. (Tokyo). Cu,Zn-superoxide
dismutase (Cu,Zn-SOD, bovine erythrocyte,
3000 U/mg solid) and NG-nitro-L-arginine methyl
ester (L-NAME) were provided by Sigma Co. (St
Louis, USA). Catalase (bovine liver, 1500 U/mg
solid) was the product of T okyo Kasei Chem.
Co. (Tokyo). Disodium cromoglycate (DSCG,
Intal®, called cromoglycate in this report) and
disodium nedocromil (called nedocromil in this
report) were synthesized in this laboratory for
experimental use. Other chemicals including
histamine ·2HCl, were analytical grade reagents
obtained from Nakalai T esk Chem. Co. (Kyoto).
Results
Dexamethasone (Dex, 0.1 mg/kg, s.c.) sup-
pressed neither ischaemic nor histamine paw
oedema at 1 h after injection. Both 1 and
10 mg/kg Dex (s.c., i.p., i.v.) failed to suppress
these oedemata at 1 h because Dex did not act
directly and needed a lag time to induce anti-
in￿ammatory protein(s). Maximum suppression
by Dex alone was observed at 3 h in ischaemic
paw oedema. Suppression of this oedema in
30 mg/kg cromoglycate- or nedocromil-treated
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increased at 3, 6, 8 and 18 h after Dex (Fig. 1A).
In histamine paw oedema, the enhancements of
suppressions by these anti-allergic drugs were
evident at 3±8 h after Dex (Fig. 1B).
As the prolonged suppressions by Dex plus
the anti-allergic drugs seemed to be bene￿cial
and important for clinical trial, the dose±
response relations of these drugs were exam-
ined at 6 h after 0.1 mg/kg Dex. Signi￿cant
increases in suppressions by Dex (0.1mg/kg,
s.c.) were found with 1±30 mg/kg cromogly-
cate or nedocromil in both models of paw
oedemata (Fig. 2A,B). Cromoglycate suppressed
ischaemic paw oedema even by 0.1 mg/kg at
6 h after Dex.
Suppression by 0.1 mg/kg Dex alone at 6 h
was slightly enhanced by 30 mg/kg SODand by
100 mg/kg L-NAME in ischaemic paw oedema.
However, SOD, catalase and cycloheximide
reversed the suppression by Dex plus cromo-
glycate. L-NAME did not change the cromogly-
cate-enhanced suppression by Dex (Fig. 3, left).
Nedocromil-enhanced Dex suppression was also
impaired by SOD, catalase and cycloheximide,
but not by L-NAME. Similar impairments of Dex
suppressions which were enhanced by cromo-
glycate or nedocromil, were also observed in
histamine paw oedema (Fig. 3, right). Endogen-
ous amount of O2- and/or H 2O2 seemed to be
essential for the increase in suppressions by
Dex plus an anti-allergic drug. Therefore, excess
scavenging of these oxidants by a redox enzyme
plus an anti-allergic drug, decreased Dex action
in our paw oedema models. L-NAME alone
suppressed both models and did not in￿uence
the suppressions of Dex that were enhanced by
cromoglycate or nedocromil. This suggested
that the role of endogenous NO was a little
inhibitory against Dex suppression. Cyclohexi-
mide co-injection always impaired the Dex
suppression, thus the protein synthesis was
required for suppression by Dex regardless of
additional administration of an anti-allergic
drug.
FIG. 1. Time-course of paw oedema suppression. (A)
Ischaemic paw oedema. (B) Histamine paw oedema. h : Dex
(0.1 mg/kg, s.c.) alone; d : Dex plus cromoglycate
(30 mg/kg, i.p.); s : Dex plus nedocromil (30 mg/kg, i.p.).
Drug was injected 30 min before Dex. Vertical lines repre-
sent standard error (SE) of means (n= 12).
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FIG. 2. Dose-response suppression of paw oedema at 6 h
after Dex (0.1 mg/kg, s.c.). (A) Ischaemic oedema. (B)
Histamine paw oedema. d : Dex + cromoglycate, s : Dex
plus nedocromil. Drug was injected 30 min before Dex.
Vertical lines represent SE of means (n= 12).
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Cromoglycate and nedocromil enhanced dexamethasone suppression in paw oedem aDiscussion
Eosinophil chemotaxis and adherence were
inhibited by 10- 5 M nedocromil.9 This anti-
allergic drug was more potent than cromo-
glycate in inhibiting the release of histamine
and leukotriene C4 (LTC4) in human mast cells.
Nedocromil, but not cromoglycate, had a pro-
tective effect in canine models with airway SO2
exposure and cough.10 Nedocromil is thus
believed to possess an anti-in￿ammatory char-
acter. Inhibition by nedocromil of superoxide
radical (O2- ) generation in human neutrophils11
and of activation of mast cells, macrophages,
eosinophils and epithelial cells12 also showed
this character. The results of a clinical double-
bind, placebo-controlled comparison with salbu-
tamol, showed that nedocromil equipotently
decreased airway in￿ammation. 12 However, the
mechanism of an anti-in￿ammatory action of
nedocromil was different with FK506 or Dex.
Sensitized and antigen-stimulated vehicle-treated
guinea pigs showed marked in￿ltration of the
bronchial wall by CD4+ T -lymphocytes and
eosinophils. FK506 and Dex abolished this
in￿ltration but nedocromil failed to abolish it,
therefore the anti-in￿ammatory effect of nedo-
cromil was not associated with T -lymphocytes
or eosinophils.13
In our experiments, cromoglycate and nedo-
cromil alone were weak in suppressing the
ischaemic and histamine paw oedema of mice
(Fig. 2A,B), but they enhanced the suppression
by a low dose (0.1 mg/kg) of Dex. Immunosup-
pressants such as FK506 failed to suppress
these oedemata, but accelerated and increased
the suppression by Dex at 3 h after Dex injec-
tion.3 Suppressions of our paw oedemata de-
creased after 3 h of 0.1 mg/kg Dex.
Cromoglycate and nedocromil (1±30 mg/kg,
i.p.) prolong the effective duration time of Dex
action up to 8 h (Fig. 1A,B) without inducing
the early appearance of oedema suppression at
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FIG. 3. Effect of inhibitor on oedema suppression by Dex alone and Dex + drug (cromoglycate or nedcromil). Tests were
performed at 6 h after Dex (0.1 mg/kg, s.c.). Drug was injected i.p. 30 min before Dex. Administration of inhibitor (i.p.) was
administered before drug. Vertical lines represent SE of mean by four times tests with three mice (n= 12, in total). and
shows statistical differences (P , 0.01 and P , 0.05 to each control, respectively). Control mice received Dex drug and no
inhibitor.
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(morin, a-tocopherol, tannic acid, rutin, biliru-
bin, b-carotene, quercetin) alone were ineffec-
tive in suppressing ischaemic and histamine
paw oedema, but prolonged the suppression
time by 0.1 mg/kg Dex (our unpublished data).
In this context, the mode of anti-allergic drug
suppression resembled those of natural antiox-
idants. The maintenance of a cellular reductive
state in target cells by these antioxidants was
supposed to be the cause for prolonging Dex
action, for the glucocorticoid receptor (GR)
complex might be more active in a reductive
state to produce Dex-inducible proteins such as
lipocortin1 or vasoregulin.2 After the mode of
oedema suppression, cromoglycate and nedo-
cromil must be similar to natural antioxidants
thereby increasing Dex-inducible anti-in￿amma-
tory proteins.
Immunosuppressants including FK506 en-
hanced the oedema suppression by Dex in a
different mode from two anti-allergic drugs and
natural antioxidants. GR complex contains heat
shock proteins (hsp)—hsp56 or cyclophilin-40
(CyP-40), hsp70, hsp90 and other unidenti￿ed
low molecular hsps. FK506 and rapamycin bind
to hsp56.14 Cyclosporin A binds to CyP-4015.
Deoxyspergualin binds to hsp70 and hsp90.
These bindings of immunosuppressants might
change the conformation of GR complex and
thus facilitate the activation of inactive GR
complex by dissociating two hsp90 molecules.
The increased entrance of activated GR com-
plex into the nucleus or enhanced attachment
of GR complex to GRE (an enhancer site on
DNA chain) is also possible by this conforma-
tional change. The possible site(s) to enhance
the signalling of glucocorticoid (GC) such as
Dex, was sensitive to a nitric oxide synthase
(NOS) inhibitor, NG-nitro-L-arginine methyl ester,
Cu,Zn-superoxide dismutase (Cu,Zn-SOD, O2
-
scavenger) and mannitol (hydroxyl radical
[·OH] scavenger).3 This is true for Dex suppres-
sion with or without additional drugs. There-
fore, the endogenous amount of NO, O2
- , H 2O2
or ·OH seemed to be essential for Dex action.
Enhancement of oedema suppression by Dex
plus anti-allergic drug, was reversed by Cu,Zn-
SOD and catalase, but not by L-NAME (Fig. 3).
Endogenous amount of NO must not be in-
volved in the enhancing action of cromoglycate
and nedocromil on Dex action in ischaemic
paw oedema. The enhancing action of natural
antioxidant (morin, bilirubin and b-carotene),
was also reversed by each 30 mg/kg (i.p.) of
Cu,Zn-SOD and catalase, but not by L-NAME
(unpublished data). Scavenging capacity of ROS
or NOS inhibitory action of cromoglycate and
nedocromil has not yet been demonstrated in
vitro, but they might behave by increasing the
intracellular reductive state just as natural anti-
oxidants. Oxidants such as hydrogen peroxide
(H 2O2) activated a transcription factor immuno-
globulin k light-chain binding nuclear factor
(NF-kB) and reduced the activity of activator
protein (AP-1).16 GR is a transcriptional factor,
therefore it is not surprising that the GC action
was supported by the endogenous amount of
superoxide radical (O2- ) or H 2O2. The modi￿ca-
tion of the GR complex by two anti-allergic
drugs seemed impossible from the mode of
action on oedema models (the lack of increased
suppression at 1 h after Dex injection). Cyclo-
heximide, a protein synthesis inhibitor, always
impaired the suppression by Dex whether Dex
alone or with a drug, indicating that the synth-
esis of anti-in￿ammatory proteins is essential for
Dex action.17 Clinical trials of combined therapy
with a diminished dose of GCand cromoglycate
or nedocromil must be hopeful for asthma and
some kind of in￿ammations expecting less
undesirable side effects of these drugs.
In conclusion, cromoglycate and nedocromil
should have a common mechanism to enhance
the suppression by low dose of Dex in ischae-
mic- and histamine-induced in￿ammations in
addition to their reported anti-allergic and anti-
in￿ammatory actions. This suppresive mechan-
ism seemed to be supported by endogenous
reactive oxygen species. Our combination ther-
apy is worthwhile of trial in the clinical ￿eld.
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